MENDLEIN JOHN
Known title: DirectorCIK: 0001238362
MENDLEIN JOHN's purchase track record
MENDLEIN JOHN has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/11/2023 | FATE | $698K | -1.9% | -13.6% | +12.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| FATE | ▲ Buy | Option Exercise | 28,461 | $39K | 1/19/2023 | View on chart |
| FATE | ▲ Buy | Open Market | 36,631 | $199K | 1/13/2023 | View on chart |
| FATE | ▲ Buy | Open Market | 88,048 | $499K | 1/11/2023 | View on chart |
| FATE | ▲ Buy | Grant | 8,650 | $0 | 6/9/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 1,364 | $31K | 6/3/2022 | View on chart |
| FATE | ▲ Buy | Option Exercise | 31,562 | $51K | 3/10/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 12,069 | $428K | 3/10/2022 | View on chart |
| FATE | ▼ Sell | Open Market | 19,493 | $677K | 3/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial
Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.
Fate Therapeutics Secures $15M CIRM Grant for Lupus Trial. Fate Therapeutics announced it received a $15 million grant from the California Institute for Regenerative Medicine to advance its Phase 2 RECLAIM-LN trial for lupus nephritis. This funding supports the development of the company's FT819 therapy. The news coincides with the stock trading near its 52-week low, providing a potential catalyst for the healthcare sector.